Answers are grounded in this paper and cite their sources.
A phase II evaluation of bruceantin was carried out in 15 patients with refractory metastatic breast cancer. All patients had received extensive prior therapy including adriamycin, cytoxan, 5-FU, methotrexate, and a vinca alkaloid. Except for two patients with stable disease, no complete or partial response was observed. Drug toxicity, mainly nonhematologic, was severe, with nausea, vomiting, mild hypotension, and fever being the most frequently encountered.
No takes yet. Share an insight, caveat, or question.
Wiseman et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: